AD/PD 2021 | CSF protein panels reflect the specific molecular fingerprint of Alzheimer’s disease

Marta Del Campo, PhD, University CEU San Pablo, Madrid, Spain, discusses a study aimed to identify panels of cerebrospinal fluid (CSF) proteins covering different molecular pathways for early and specific diagnosis of Alzheimer’s disease. Using proximity ligation-based multiplex immunoassays, more than 900 proteins were analyzed in CSF samples from patients with Alzheimer’s disease, non-Alzheimer’s dementias, mild cognitive impairment with amyloid pathology (MCI-Aβ+), and non-demented controls. The results showed that several proteins were specific for Alzheimer’s and that some of the dysregulated proteins were different in the early Alzheimer’s stage compared to the late stage of the disease. Additionally, the study identified and validated protein panels linked to multiple Alzheimer’s disease-related mechanisms. This interview took place during the AD/PD™ 2021 conference.